SCHEMBL23945277

SCHEMBL23945277

CCC(C)CN(C)CCCc1ccc(C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 8/20 0.41
KCNH2 Q12809 3/20 0.40
IGF1R P08069 1/20 0.37
ALOX15 P16050 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2A6 P11509 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 2/20 0.35
CHRM2 P08172 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
CHRM1 P11229 1/20 0.35
DRD1 P21728 1/20 0.35
ADRA1A P35348 1/20 0.35
OPRM1 P35372 1/20 0.35
DRD3 P35462 1/20 0.35
AOC3 Q16853 1/20 0.35
HRH1 P35367 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19493337 0.78 SIGMAR1 (0.52) SIGMAR1KCNH2
SCHEMBL22624601 0.78 SIGMAR1 (0.61) SIGMAR1KCNH2IGF1RALOX15CYP1A2
SCHEMBL28350462 0.75 CYP1A2 (0.43) KCNH2IGF1RALOX15CYP1A2CYP2A6
SCHEMBL23954013 0.73 KCNH2 (0.53) SIGMAR1KCNH2CYP1A2CYP2A6TAAR1
SCHEMBL29347996 0.73 PYCR1 (0.35) SIGMAR1KCNH2SLC6A4
SCHEMBL26408085 0.73 TAAR1 (0.43) SIGMAR1KCNH2ALOX15CYP1A2TAAR1
SCHEMBL19146986 0.73 SIGMAR1 (0.55) SIGMAR1KCNH2IGF1RALOX15CYP1A2
SCHEMBL19936946 0.70 GGPS1 (0.41)
SCHEMBL21770967 0.70 PYCR1 (0.46) SIGMAR1KCNH2SLC6A2SLC6A4
SCHEMBL5948692 0.70 TSHR (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 SIGMAR1 3199/4885KCNH2 4751/4885IGF1R 540/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 SIGMAR1 3199/4885KCNH2 4751/4885IGF1R 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.